With commercial insurance: OCREVUS Co-pay Program — as little as $0, up to $20,000 per calendar year. With Medicare: the Ocrevus Zunovo card can’t be used. TotalAssist (Patient Advocate Foundation) – Multiple sclerosis (MS) is open as of September 28, 2026.
See what this patient owes after assistance →
7 assistance programs for Ocrevus Zunovo patients · 3 open today
Two Genentech programs: a copay card for commercial insurance, and a free-drug foundation for uninsured patients — neither reaches a Medicare patient's coinsurance.
Select the patient's insurance to see which programs may apply.
Current status · Award amounts · Eligibility · Direct application links September 29, 2026
Ocrevus Zunovo · Relapsing-remitting MS · Commercial insurance
Eligible patients may pay $0
Example · Ocrevus Zunovo · 920 mg · 920 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With OCREVUS Co-pay Program (same program covers OCREVUS ZUNOVO) | |
|---|---|---|
| Drug responsibility | $8,700.81 | $0.00 |
| Administration (96401) | $14.36 | $0.00 |
| Patient owes | $8,715.17 | $0.00 |
Estimated patient savings: $8,715.17
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Maximum award $8,000
PAN Foundation fund for government-insured patients with Multiple sclerosis (MS) (confirmed diagnosis).
Maximum award Contact Good Days
Good Days fund for government-insured patients with Multiple Sclerosis (confirmed diagnosis).
Maximum award $8,000
HealthWell Foundation fund for government-insured patients with Multiple Sclerosis (confirmed diagnosis).
Also available if this patient’s coverage falls short
Free Genentech Patient Foundation for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
| Task | ✓ |
|---|---|
| Find programs for this insurance type | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance — Eligible commercially insured patients may qualify for the Ocrevus Co-pay Program. Eligible patients may pay as little as $0 per treatment: the program covers up to $20,000 a year toward the drug and up to $1,500 toward administration in the first year ($1,000 each year after), subject to current program terms. The $1,500 administration cap comfortably covers the $71.81 96401 line, so for a commercially insured patient on this program the contested 96401-vs-96372 question is a billing detail for the practice, not a cost to the patient. The $20,000 drug cap is a payout ceiling, not a promise: it is less than half of $43,504.04, the Medicare-allowed drug amount for one 920 mg dose. View current program ↑
Medicare — Manufacturer copay savings cannot be used when government insurance is paying for Ocrevus Zunovo; the federal Anti-Kickback Statute is why, per HHS OIG guidance on copayment coupons. The Genentech Patient Foundation is not a fallback either: it is open only to uninsured patients. View current options ↑
Medicaid — The Ocrevus Co-pay Program's own eligibility terms exclude Medicaid alongside Medicare, TRICARE, VA and other government programs, for the same Anti-Kickback reasons.
Uninsured — The Genentech Patient Foundation provides free Ocrevus Zunovo to qualifying patients who meet the program's income rules who are US residents. It does not cover the injection administration fee or the office visit — drug cost only. Check today's status ↑
Why fund status matters — Manufacturer programs can change between: OPEN Accepting applications now · WAITLIST Not enrolling immediately · CLOSED Not accepting new applications. Every CareCost program card shows the status and the date it was verified.
Why the product name matters — Ocrevus Zunovo, infused Ocrevus and Briumvi are three different products with three different assistance programs, even though the first two share the ocrelizumab molecule. Confirm which product the patient is actually prescribed before applying.
Yes. The Ocrevus Co-pay Program is Genentech's manufacturer savings program for Ocrevus Zunovo. Eligible commercially insured patients may pay as little as $0 per treatment: the program covers up to $20,000 a year toward the drug and up to $1,500 toward administration in the first year ($1,000 each year after). Apply on Ocrevus.com ↗ Calculate cost with the program →
No. Patients using Medicare or other government-funded insurance to pay for Ocrevus Zunovo are not eligible for Genentech's copay program, per federal Anti-Kickback Statute rules on copay coupons. The Genentech Patient Foundation is not a fallback either — it covers uninsured patients only. Check current options ↑
Yes. The Genentech Patient Foundation provides free Ocrevus Zunovo to qualifying uninsured or underinsured patients who meet the program's income rules. It does not cover the injection administration fee. Check today's status ↑
Not all the way for the drug. The Ocrevus Co-pay Program's $20,000 annual drug cap is less than half of $43,504.04, the Medicare-allowed drug amount for one 920 mg dose. The program can take a commercially insured patient's per-treatment drug copay to $0 until the year's $20,000 is used up; after that the plan's normal cost-sharing applies again. The program's separate $1,500 administration cap (year one) comfortably covers the $71.81 96401 line.
Data current: programs verified Sep 29, 2026
OCREVUS Co-pay Program Program · Genentech Patient Foundation. Every program links directly to its official source or application page.
Last program check: .
Reviewed September 13, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost